Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of ribavirin in preparing medicine for treating ischemic cerebral apoplexy

A technology for treating ischemic stroke and drugs, applied in drug combinations, medical preparations containing active ingredients, sugar-coated pills, etc. Herpes, no pharmacological properties and other problems have been found to achieve the effect of improving the volume of brain tissue necrosis, expanding clinical indications, and highlighting the promotion prospect

Inactive Publication Date: 2016-03-23
李慧
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore ribavirin is mainly applied as an antiviral drug in the prior art, and its scope of indications includes Lassa fever, infant respiratory syncytial virus pneumonia, type A, type B influenza and parainfluenza virus infection, epidemic hemorrhagic fever, Herpes simplex, measles, parotitis, chickenpox, herpes zoster, etc. It can be seen that ribavirin has no pharmacological properties other than antiviral in the prior art

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ribavirin in preparing medicine for treating ischemic cerebral apoplexy
  • Application of ribavirin in preparing medicine for treating ischemic cerebral apoplexy
  • Application of ribavirin in preparing medicine for treating ischemic cerebral apoplexy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] 1. Preparation of drugs

[0026] Take 50g of ribavirin and 2450g of starch, mix 950g of starch with water to make a thin slurry, then gradually add the remaining starch and all the ribavirin to the slurry under stirring, stir everything evenly to make granules, and then Sieve, dry, and pack into capsules.

[0027] 2. Selection of experimental objects

[0028] Randomly select 100 patients with onset time of more than 4.5 hours but less than 48 hours as experimental subjects, patients with large artery atherosclerosis and lacunar necrosis with necrosis volume exceeding 5ml, and without arrhythmia, macular edema, tumor and immunosuppression The patients who received the drug were used as the experimental subjects, and 100 people were matched with clinical and imaging characteristics as controls.

[0029] 3. Experimental method

[0030] The patients were divided into a ribavirin treatment group and a control group, the control group received standard ischemic stroke trea...

Embodiment 2

[0040] Take 50g of ribavirin and 2450g of starch, mix 950g of starch with water to make a thin slurry, then gradually add the remaining starch and all the ribavirin to the slurry under stirring, stir everything evenly to make granules, and then Sieve and dry to form granules.

Embodiment 3

[0042] Take 50g of ribavirin, 2300g of starch, and 150g of magnesium stearate, mix 950g of starch and water to make a thin slurry, and then gradually add the remaining starch, all of the ribavirin and all of the stearin to the slurry while stirring Magnesium acid, all stirred evenly, dried and compressed into tablets, film-coated to form tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of ribavirin in preparing a medicine for treating ischemic cerebral apoplexy. Upon experimental means, the ribavirin can achieve an effect on treating inflammations by relieving a lymphocytes infiltration phenomenon caused by the ischemic cerebral apoplexy, and subsequently a therapeutic effect can be achieved on the ischemic cerebral apoplexy. According to the invention, the clinical applicability of the ribavirin and structural analogues thereof is widened; and the internal principle that lymphocytes participate in the pathological damage of the ischemic cerebral apoplexy is revealed. The medicine disclosed by the invention, through oral administration, can significantly diminish the necrosis volume of brain tissue, reduce inflammatory exudation amount of intra-cerebral vessels and relieve an edema phenomenon of the brain tissue; and the medicine has a significant curative effect on the ischemic cerebral apoplexy and has an outstanding prospect of popularization.

Description

technical field [0001] The invention relates to the technical field of cerebrovascular disease treatment, in particular to the application of ribavirin in the preparation of ischemic cerebral apoplexy medicine. Background technique [0002] Ischemic stroke refers to brain tissue necrosis disease caused by stenosis or occlusion of cerebral blood supply arteries (carotid artery and vertebral artery) and insufficient cerebral blood supply. It is the main type of cerebrovascular disease, accounting for about 85% of the total number of stroke cases. %. Due to the suddenness of this disease and the serious pathological damage, unless it is detected in time and treated, it will cause irreversible damage to the brain tissue. The treatment methods for ischemic stroke in the prior art mainly include thrombolytic therapy, anticoagulation, neuroprotection, surgery, etc. However, clinically, unless thrombolysis is effective within 5 hours, other methods are difficult to significantly im...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7056A61P9/10
CPCA61K9/1652A61K9/2059A61K9/28A61K9/4866A61K31/7056
Inventor 李慧
Owner 李慧
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com